Immune therapy of multiple sclerosis - future strategies

Current Pharmaceutical Design

Volumn 18, Issue 29, 2012, Pages 4489-4497

  Meuth, Sven G ^a   Göbel, Kerstin ^a   Wiendl, Heinz ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Alemtuzumab; BG00012; Cladribine; Daclizumab; Fingolimod; Laquinimod; Multiple sclerosis; Teriflunomide

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; BG 00012; CLADRIBINE; DACLIZUMAB; FAG 201; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; LAQUINIMOD; OCRELIZUMAB; OFATUMUMAB; TERIFLUNOMIDE; UNCLASSIFIED DRUG;

ALOPECIA; ARTHRALGIA; ATRIOVENTRICULAR BLOCK; BACKACHE; BRADYCARDIA; COMMON COLD; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GASTROINTESTINAL DISEASE; HAIR LOSS; HEADACHE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTENSION; IMMUNOTHERAPY; INJECTION SITE REACTION; LIVER NECROSIS; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NAUSEA; NEOPLASM; PANCYTOPENIA; PARESTHESIA; PRIORITY JOURNAL; RETINA MACULA EDEMA; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SKIN CANCER; TREATMENT OUTCOME; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; DRUG APPROVAL; DRUG DESIGN; EUROPE; HUMANS; IMMUNOLOGIC FACTORS; MEDICATION ADHERENCE; MULTIPLE SCLEROSIS; UNITED STATES;

EID: 84866413167     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802502198     Document Type: Review

References (49)

1. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992; 340(8825): 952-956.
2. Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 2005; 5(6): 721-727
3. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 1996; 93(4): 1716-1720.
4. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Development of cladribine treatment in multiple sclerosis. Mult Scler 1996; 1(6): 343-347
5. Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E. A double blind, placebo-controlled, randomized trial of cladribine in relapsing- remitting multiple sclerosis. Proc Assoc Am Physicians 1999; 111(1): 35-44.
6. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 416-426.
7. Hiestand PC, Rausch M, Meier DP, Foster CA. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720. Prog Drug Res 2008; 66:361: 363-381.
8. Linker RA, Kieseier BC, Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 2008; 29(11): 558-565.
9. Coelho RP, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 2007; 323(2): 626-635.
10. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008; 63(1): 61-71.
11. Mullershausen F, Craveiro LM, Shin Y, et al. Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1- phosphate receptors. J Neurochem 2007; 102(4) 1151-1161.
12. Balatoni B, Storch MK, Swoboda EM, et al. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 2007; 74(5): 307-316.
13. Fujino M, Funeshima N, Kitazawa Y, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003; 305(1): 70-77.
14. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355(11): 1124-1140.
15. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362(5), 402-415.
16. Lim SY, Constantinescu CS. Current and future disease-modifying therapies in multiple sclerosis. Int J Clin Pract 2010; 64(5): 637-650.
17. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 387-3401.
18. Lee DH, Linker RA, Gold R. Spotlight on fumarates. Int MS J 2008; 15(1): 12-18.
19. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372(9648): 1463-1472.
20. Brunmark C, Runstrom A, Ohlsson L, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 130(1-2): 163-172.
21. Jonsson S, Andersson G, Fex T, et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structureactivity relationship. J Med Chem 2004; 47(8): 2075-2088.
22. Runstrom A, Leanderson T, Ohlsson L, Axelsson B. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. J Neuroimmunol 2006; 173(1-2): 69-78.
23. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004; 156(1-2): 3-9.
24. Preiningerova J. Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin Investig Drugs 2009; 18(7): 985-989.
25. Polman C, Barkhof F, Sandberg-Wollheim M, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005; 64(6): 987-991.
26. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRImonitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebocontrolled phase IIb study. Lancet 2008; 371(9630): 2085-2092.
27. Korn T, Magnus T, Toyka K, Jung S. Modulation of effector cellfunctions in experimental autoimmune encephalomyelitis by leflunomide-- mechanisms independent of pyrimidine depletion. J Leukoc Biol 2004; 76(5): 950-960.
28. Kaplan MJ. Leflunomide Aventis Pharma. Curr Opin Investig Drugs 2001; 2(2): 222-230.
29. Korn T, Toyka K, Hartung HP, Jung S. Suppression of experimental autoimmune neuritis by leflunomide. Brain 2001; 124(9): 1791-1802.
30. Smolen JS, Emery P, Kalden JR, et al. The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. J Rheumatol Suppl 2004; 71: 13-20.
31. O'Connor PW, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66(6): 894-900.
32. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365(14):1293-1303.
33. Hale G, Bright S, Chumbley G, et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983; 62(4): 873-882.
34. Reiff A. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology 2005; 10(2): 79-93.
35. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253(1): 98-108.
36. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354(9191): 1691-1695.
37. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46(3): 296-304.
38. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359(17): 1786-1801.
39. Fox EJ, Sullivan HC, Gazda SK, et al. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Eur J Neurol 2012;19(2):307-311.
40. Buttmann M, Rieckmann P. Treating multiple sclerosis with monoclonal antibodies. Expert Rev Neurother 2008; 8(3): 433-455.
41. Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Expert Rev Neurother 2010; 10(5): 791-809.
42. Waldmann TA, O'Shea J. The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol 1998; 10(5): 507-512.
43. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti- Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA 1999; 96: 7462-746.
44. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103(15): 5941-5946.
45. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 2004; 101(23): 8705-8758.
46. Rose JW, Watt HE, White, AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004; 56(6): 864-867.
47. Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007; 69(8): 785-789.
48. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010; 9(4): 381-390.
49. Comi G, Jeffery D, kappos L, et al. Placedo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012; 366 (11):1000-1009.